GeneDx Holdings
About: GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.
Employees: 1,000
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
34% more repeat investments, than reductions
Existing positions increased: 86 | Existing positions reduced: 64
16% more capital invested
Capital invested by funds: $2.51B [Q1] → $2.91B (+$397M) [Q2]
10% more first-time investments, than exits
New positions opened: 53 | Existing positions closed: 48
9.37% more ownership
Funds ownership: 100.99% [Q1] → 110.36% (+9.37%) [Q2]
2% more funds holding
Funds holding: 224 [Q1] → 228 (+4) [Q2]
8% less funds holding in top 10
Funds holding in top 10: 12 [Q1] → 11 (-1) [Q2]
16% less call options, than puts
Call options by funds: $210M | Put options by funds: $252M
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
|
Piper Sandler
David Westenberg
|
$140
|
Overweight
Maintained
|
11 Sep 2025 |
|
Wells Fargo
Brandon Couillard
|
$95
|
Equal-Weight
Maintained
|
30 Jul 2025 |
|
Guggenheim
Subbu Nambi
|
$115
|
Buy
Maintained
|
30 Jun 2025 |
Financial journalist opinion
Based on 11 articles about WGS published over the past 30 days
